Teleflex’s second quarter results were marked by positive market reaction, driven largely by operational outperformance in its Interventional segment and effective margin management. Management attributed the quarter’s success to strong growth in intra-aortic balloon pumps, double-digit gains from OnControl and complex catheters, and ongoing efforts to offset cost headwinds in raw materials and logistics. CEO Liam Kelly highlighted the importance of these product categories, stating, “The upside in Interventional actually was delivered by OnControl and complex catheters.” Additionally, sequential improvement in China and progress in addressing tariff exposure contributed to the company’s results.

Is now the time to buy TFX? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Teleflex’s Q2 Earnings Call

• Matt Taylor (Jefferies) asked about the organic growth outlook for the BIOTRONIK Vascular Intervention business. CEO Liam Kelly confirmed expectations for mid-single-digit growth in the second half and 6% or better annually starting in 2026.
• Jayson Bedford (Raymond James) inquired about the durability of Interventional segment growth. Kelly responded that core drivers like OnControl and complex catheters delivered the upside and reiterated a full-year outlook of high single to low double-digit growth.
• Anthony Petrone (Mizuho Americas) sought clarity on the timeline and process for the NewCo separation or sale. Kelly explained that while a spin could occur mid-2026, the timing of a sale is less certain, with substantial due diligence underway.
• Richard Newitter (Truist) questioned the impact of CMS’s proposed reimbursement rules on the Urology business. Kelly stated that if enacted as proposed, the rules would provide a significant boost to office-based procedures and help UroLift recover.
• Michael Matson (Needham) wanted details about the integration of BIOTRONIK’s sales force and risks of disruption. Kelly outlined that complementary geographic strengths would enable broader coverage and that integration is expected to create revenue synergies without major disruption.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace and effectiveness of BIOTRONIK Vascular Intervention’s integration and its impact on Interventional segment growth; (2) additional progress on tariff mitigation and the realization of planned price increases; and (3) regulatory developments around CMS reimbursement rules for Urology. Execution on these fronts will be critical for sustaining revenue momentum and margin expansion.

Teleflex currently trades at $119.64, up from $113.93 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

The Best Stocks for High-Quality Investors

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.